Neoadjuvant Therapy
Aspirin may have ‘direct role’ in augmenting the immune system to fight colorectal cancer
Whereas previous studies have shown aspirin use decreases incidence and mortality of colorectal cancer, researchers may now have insight into why this occurs, according to study results published in Cancer.
Race identified as risk factor for VTE after pulmonary resection for lung cancer
Black patients and those with interstitial fibrosis or advanced-stage disease had a higher risk for developing clinically detectable postoperative venous thromboembolism after pulmonary resection for lung cancer, study results showed.
Racial, ethnic disparities emerge after neoadjuvant therapy for gastric cancer
There are significant differences in response to treatment and survival outcomes for certain racial and ethnic groups among patients with resected stage II or stage III gastric cancer, study findings published in JAMA Network Open showed.
Some patients with stage III melanoma can avoid surgery after neoadjuvant immunotherapy
CHICAGO — Tumor lymph node dissection likely can be omitted for patients with melanoma who achieve major pathologic response after neoadjuvant immune checkpoint blockade, according to study results presented at ASCO Annual Meeting.
Long-course chemoradiation may improve organ preservation rates in rectal cancer
A long course of chemoradiation therapy appeared associated with higher organ preservation rates vs. a short course among a cohort of patients with rectal cancer, according to a study presented at ASCO Gastrointestinal Cancers Symposium.
Neoadjuvant immunotherapy a potential new standard of care for localized colorectal cancer
Neoadjuvant treatment with immune checkpoint inhibitors for colorectal cancer induced clinical responses that helped delay or prevent surgical resection, results of a study in Journal of the National Comprehensive Cancer Network showed.
Metabolic imaging predicts neoadjuvant therapy response before pancreatic cancer surgery
The addition of 18-fluorodeoxyglucose to PET provided significant prognostic benefit in objective assessment of neoadjuvant chemotherapy response among patients with borderline resectable/locally advanced pancreatic cancer.
VIDEO: Adjuvant, neoadjuvant therapy in non-small cell lung cancer is ‘here to stay’
Narjust Florez (Duma), MD, discusses results from two studies presented at World Conference on Lung Cancer — IMpower010 and NADIM-2
Treatment efficacy score may better predict long-term survival in breast cancer trials
Researchers led by a Yale University team have developed a new measure for neoadjuvant chemotherapy efficacy for use in preoperative breast cancer trials.
Neoadjuvant immunotherapy effective regardless of race in triple-negative breast cancer
Results of a phase 1/phase 2 study showed similar treatment outcomes among Black and non-Black women who received durvalumab plus chemotherapy prior to surgery for triple-negative breast cancer.